sunitinib malate
information and resources from the National Cancer Institute
sunitinib malate
The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. sunitinib malate
The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.
|
|
|
|
news articles
New Therapies Target Cancer Mar 7, 2006
Drug Discovery & Development (subscription), In January, the FDA approved Sutent (sunitinib malate) for the treatment of GIST and advanced kidney cancer, the first time the agency has approved a new ...
Multi-Targeted Inhibitor, SU11248, Active in Renal Cell Carcinoma Dec 12, 2005
Cancer Consultants (press release), A multi-center trial has found that sunitinib malate (SU11248), an inhibitor of vascular endothelial growth factor (VEGF) receptor and platelet derived growth ...
GlaxoSmithKline cancer drug threatens Herceptin market Dec 9, 2005
Nature.com (subscription), Several multitargeted therapies follow close behind in phase 2 trials: Pfizer's Sutent (sunitinib malate), Bayer's Nexavar (sorafenib) and AstraZeneca's ZD6474 ...
Sunitinib Promising for Metastatic Renal Cell Carcinoma Nov 18, 2005
Cancer Consultants (press release), According to results recently presented at the 2005 Chemotherapy Foundation Symposium, the oral agent sunitinib malate (SU11248), still in clinical trials ...
|
|
